Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Cereb Blood Flow Metab ; 34(1): 144-52, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24129748

ABSTRACT

Neuronal damage shortly after onset or after brief episodes of cerebral ischemia has remained difficult to assess with clinical and preclinical imaging techniques as well as with microscopical methods. We here show, in rodent models of middle cerebral artery occlusion (MCAO), that neuronal damage in acute focal cerebral ischemia can be mapped with single-cell resolution using thallium autometallography (TlAMG), a histochemical technique for the detection of the K(+)-probe thallium (Tl(+)) in the brain. We intravenously injected rats and mice with thallium diethyldithiocarbamate (TlDDC), a lipophilic chelate complex that releases Tl(+) after crossing the blood-brain barrier. We found, within the territories of the affected arteries, areas of markedly reduced neuronal Tl(+) uptake in all animals at all time points studied ranging from 15 minutes to 24 hours after MCAO. In large lesions at early time points, areas with neuronal and astrocytic Tl(+) uptake below thresholds of detection were surrounded by putative penumbral zones with preserved but diminished Tl(+) uptake. At 24 hours, the areas of reduced Tl(+)uptake matched with areas delineated by established markers of neuronal damage. The results suggest the use of (201)TlDDC for preclinical and clinical single-photon emission computed tomography (SPECT) imaging of hyperacute alterations in brain K(+) metabolism and prediction of tissue viability in cerebral ischemia.


Subject(s)
Brain/pathology , Chelating Agents , Ditiocarb , Ischemic Attack, Transient/pathology , Neurons/pathology , Thallium , Acute Disease , Animals , Autoradiography , Brain/diagnostic imaging , Brain/metabolism , Brain Mapping , Chelating Agents/administration & dosage , Disease Models, Animal , Ditiocarb/administration & dosage , Histocytochemistry/methods , Ischemic Attack, Transient/diagnostic imaging , Ischemic Attack, Transient/metabolism , Male , Mice , Mice, Inbred C57BL , Neurons/diagnostic imaging , Neurons/metabolism , Potassium/metabolism , Rats , Rats, Sprague-Dawley , Thallium Radioisotopes/administration & dosage , Tomography, Emission-Computed, Single-Photon/methods
2.
Cell Transplant ; 21(12): 2587-602, 2012.
Article in English | MEDLINE | ID: mdl-22889472

ABSTRACT

Human induced pluripotent stem cells (hiPSCs) are a most appealing source for cell replacement therapy in acute brain lesions. We evaluated the potential of hiPSC therapy in stroke by transplanting hiPSC-derived neural progenitor cells (NPCs) into the postischemic striatum. Grafts received host tyrosine hydroxylase-positive afferents and contained developing interneurons and homotopic GABAergic medium spiny neurons that, with time, sent axons to the host substantia nigra. Grafting reversed stroke-induced somatosensory and motor deficits. Grafting also protected the host substantia nigra from the atrophy that follows disruption of reciprocal striatonigral connections. Graft innervation by tyrosine hydoxylase fibers, substantia nigra protection, and somatosensory functional recovery were early events, temporally dissociated from the slow maturation of GABAergic neurons in the grafts and innervation of substantia nigra. This suggests that grafted hiPSC-NPCs initially exert trophic effects on host brain structures, which precede integration and potential pathway reconstruction. We believe that transplantation of NPCs derived from hiPSCs can provide useful interventions to limit the functional consequences of stroke through both neuroprotective effects and reconstruction of impaired pathways.


Subject(s)
Brain/pathology , Induced Pluripotent Stem Cells/cytology , Stroke/therapy , Animals , Brain/metabolism , Cell Differentiation , Cell Line , Embryoid Bodies/pathology , GABAergic Neurons/cytology , GABAergic Neurons/metabolism , Humans , Neural Stem Cells/cytology , Neural Stem Cells/transplantation , Teratoma/pathology , Transcription Factors/genetics , Transcription Factors/metabolism , Tyrosine 3-Monooxygenase/metabolism
3.
J Neurosci Methods ; 177(1): 149-59, 2009 Feb 15.
Article in English | MEDLINE | ID: mdl-19007815

ABSTRACT

Bromodeoxyuridine incorporates into DNA during mitosis. A long-term stability of the incorporated BrdU is important for the recovery of BrdU-labeled cells. For testing the stability of BrdU incorporation into DNA we pulse-labeled mesenchymal stem cells with BrdU and observed these cells in vitro over 4 weeks. During this time the BrdU-signal was permanently decreasing. Starting with cells containing evenly stained BrdU-nuclei, so-called filled cells, already 3 days after BrdU removal we detected cells containing so-called segmented and punctated BrdU-signals. The number of those labeled cells continuously increased over time. Interestingly, the loss of BrdU in the nucleus was accompanied by an increasing labeling of the cytosol. Further, we injected BrdU intraperitoneally into rats after ischemia and detected BrdU-positive cells in the hippocampus 3 and 23 days after the last BrdU injection. While after 3 days most of the BrdU-positive cells in the hippocampus displayed a filled BrdU-signal, 23 days after BrdU removal an increased number of segmented and punctated BrdU-positive nuclei was detected. The gradual degradation of the BrdU-signal was not caused by cell death. The consequence of this BrdU degradation would be an underestimation of cell proliferation and an overestimation of cell death of newly generated cells.


Subject(s)
Bone Marrow Cells/cytology , Bromodeoxyuridine/metabolism , Cell Proliferation , Mesenchymal Stem Cells/physiology , Animals , Apoptosis/drug effects , Bone Marrow Cells/drug effects , Caspase 3/metabolism , Cell Count , Cells, Cultured , Cytochromes c/metabolism , Doublecortin Domain Proteins , Enzyme Inhibitors/pharmacology , Hippocampus/pathology , Ischemia/pathology , Mesenchymal Stem Cells/drug effects , Microtubule-Associated Proteins/metabolism , Neuropeptides/metabolism , Phosphopyruvate Hydratase/metabolism , Rats , Rats, Sprague-Dawley , Statistics, Nonparametric , Staurosporine/pharmacology , Time Factors
4.
Neurosci Lett ; 432(2): 141-5, 2008 Feb 20.
Article in English | MEDLINE | ID: mdl-18222610

ABSTRACT

The mouse model of transcranial permanent occlusion of the middle cerebral artery (tpMCAO) is widely used in stroke research. Here we quantified infarct size using a conventional histological method at several post-ischaemic times, going beyond the commonly analysed period of up to 2 days, following artery occlusion. Two different mouse strains, which are widely used for pharmacological studies of neuroprotection and for genetic engineering, were used. A drill whole was made into the skull of anaesthetised mice and ischaemia was induced by electrocoagulation of the middle cerebral artery. In both mouse strains tested (C57Black/6 and NMRI), the measured infarct volumes decreased significantly during the first days after tpMCAO. Notably, 13 days after surgery, ischaemic and sham-operated animals had indistinguishably small lesions, which where in the range of only 5% of the infarct size on day 2 post-ischaemia. The standard method of calculating oedema and shrinkage correction provided no sufficient explanation for this significant decrease in infarct volume. There was, however, evidence that structural changes in the residual ipsilateral hemisphere may compromise the significance of results arising from the method of calculating oedema and shrinkage correction. In conclusion, our study indicates that the pronounced and fast, time-dependent decrease in histologically defined infarct volume can compromise results when studying the lasting neuroprotective effects of potential drugs.


Subject(s)
Brain Edema/pathology , Brain Infarction/pathology , Brain Ischemia/pathology , Brain/pathology , Animals , Artifacts , Brain/drug effects , Brain/physiopathology , Brain Edema/drug therapy , Brain Edema/physiopathology , Brain Infarction/drug therapy , Brain Infarction/physiopathology , Brain Ischemia/drug therapy , Brain Ischemia/physiopathology , Disease Models, Animal , Disease Progression , Drug Evaluation, Preclinical/standards , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/physiopathology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Neuroprotective Agents/pharmacology , Time Factors
5.
J Neurosci Methods ; 162(1-2): 14-8, 2007 May 15.
Article in English | MEDLINE | ID: mdl-17197033

ABSTRACT

The influence of anaesthesia in experimental stroke research is controversial. We addressed this problem using the model of endothelin-1-induced occlusion of the middle cerebral artery (eMCAO). This model provided the opportunity to compare the infarct volumes of rats which were under halothane anaesthesia during eMCAO induction with the lesions of rats which were without anaesthesia during eMCAO. All animals were implanted with guide cannulae which allowed the induction of ischaemia in freely moving animals. For comparison, one group of animals was exposed to halothane during the induction of ischaemia. Seven days after eMCAO, the average infarct volume of halothane-anaesthetised rats was significantly larger than the lesion in freely moving animals. This difference was mainly due to increased cortical damage, whereas the striatum was much less influenced. The cortical infarct volume 21 days after induction of eMCAO under anaesthesia was significantly reduced compared to the infarct volume 7 days after eMCAO under anaesthesia. Our results indicate that halothane anaesthesia during eMCAO can cause a transient cortical increase in ischaemic infarct volume. The influence of volatile anaesthetics on ischaemic pathophysiology should be taken into consideration when preclinically testing potential neuroprotective drugs for clinical applications.


Subject(s)
Brain Ischemia/chemically induced , Cerebral Infarction/chemically induced , Endothelin-1/pharmacology , Endothelium, Vascular/pathology , Halothane/toxicity , Middle Cerebral Artery/pathology , Anesthetics, Inhalation/toxicity , Animals , Brain Ischemia/pathology , Cerebral Infarction/pathology , Endothelium, Vascular/drug effects , Male , Middle Cerebral Artery/drug effects , Rats , Rats, Sprague-Dawley
6.
Brain Res ; 1070(1): 232-41, 2006 Jan 27.
Article in English | MEDLINE | ID: mdl-16403464

ABSTRACT

Thrombin significantly influences neurodegenerative processes after ischemia. The current literature suggests that the effects are mediated via protease-activated receptors 1, 3 and 4 (PAR1, 3, 4). Therefore, we investigated with immunohistochemical methods whether focal cerebral ischemia altered the expression of PARs in the rodent brain. For this purpose, we used the model of endothelin-induced occlusion of the middle cerebral artery and the model of transcranial permanent occlusion of the middle cerebral artery in mice. In contrast to the exclusively neuronal staining in the brain parenchyma of naïve animals, PAR1 and PAR3 occurred in addition on microglial cells in the penumbra after transient and after permanent focal ischemia. Although microglia activation could be detected for several weeks after the insult, PAR1 and PAR3 were traceable on microglia only 12 and 48 h after the insult, but not on day 7 post-ischemia. PAR4 was expressed, both in naïve and in ischemic animals, exclusively in neuronal cells. However, at the border zone and within the infarct area, enhanced immunohistochemical PAR4 signals were recognized. From our data, we conclude that PAR1 and PAR3 could be involved in thrombin-modulated initiation of post-ischemic inflammation and PAR4 may be associated with neuronal degeneration.


Subject(s)
Brain Ischemia/metabolism , Brain/metabolism , Microglia/metabolism , Receptor, PAR-1/metabolism , Receptors, Thrombin/metabolism , Animals , Brain/pathology , Brain Ischemia/pathology , Immunohistochemistry , Male , Rats , Rats, Sprague-Dawley , Tissue Distribution
7.
Brain Res ; 1056(2): 158-67, 2005 Sep 21.
Article in English | MEDLINE | ID: mdl-16125154

ABSTRACT

The persistence of neurogenesis in the adult mammalian forebrain suggests that endogenous precursors may be a potential source for neuronal replacement after injury or neurodegeneration. On the other hand basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) can facilitate neural precursor proliferation in the adult rodent subventricular zone (SVZ) and dentate gyrus. As the application of EGF and bFGF was found to boost neurogenesis after global ischemia, in this study we investigated whether a combined intracerebroventricular (i.c.v.) EGF/bFGF treatment over a period of 2 weeks affects the proliferation of newly generated cells in the endothelin-1 model of transient focal ischemia in adult male Sprague-Dawley rats as well. As assessed by toluidine blue staining, EGF/bFGF substantially increased the infarct volume in ischemic animals. Chronic 5'-bromodeoxyuridine (BrdU) i.c.v. application revealed an EGF/bFGF-induced increase in cell proliferation in the lateral ventricle 14 days after surgery. Proliferation in the striatum increased after ischemia, whereas in the dentate gyrus and in the dorsal 3rd ventricle the number of cells decreased. Analysis of the neuronal fate of these cells by co-staining with a doublecortin (DCX) antibody showed that the growth factors concomitantly nearly doubled early neurogenesis in the ipsilateral striatum in ischemic animals but diminished it in the dentate gyrus. Because of the increased infarct volume and unclear long-term outcome further modifications of a chronic treatment schedule are needed before final conclusions concerning the perspectives of such an approach can be made.


Subject(s)
Brain Infarction/prevention & control , Cell Proliferation/drug effects , Epidermal Growth Factor/therapeutic use , Fibroblast Growth Factor 2/therapeutic use , Ischemic Attack, Transient/drug therapy , Analysis of Variance , Animals , Brain Infarction/etiology , Brain Infarction/pathology , Bromodeoxyuridine/metabolism , Cell Count/methods , Disease Models, Animal , Doublecortin Domain Proteins , Doublecortin Protein , Drug Interactions , Endothelin-1/pharmacology , Functional Laterality/physiology , Immunohistochemistry/methods , Infarction, Middle Cerebral Artery/complications , Ischemic Attack, Transient/pathology , Male , Microtubule-Associated Proteins/metabolism , Neuropeptides/metabolism , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...